Allogeneic hematopoietic stem cell transplantation (allo-HCT) is used to treat a variety of hematologic conditions. Many patient characteristics impact outcomes, including age, comorbidities, performance status and baseline respiratory function. 1, 2 Cigarette smoking can influence these factors and therefore impact transplant eligibility, with the lifetime prevalence of smoking among patients who ultimately undergo hematopoietic stem cell transplant (HSCT) ranging from 22 to 62%. 3, 4 Despite the wellestablished health implications of cigarette smoking on various diseases including cancer, only a limited number of studies have evaluated its impact on outcome following allo-HSCT. [3] [4] [5] [6] In addition, tobacco cigarettes contain fungal elements that could potentially lead to invasive fungal infections (IFIs), which are considered among the most dangerous complications of allo-HSCT. While smoking has been reported to be associated with infectious pulmonary complications, the association with IFI remains unclear. 5, 7 We therefore evaluated the hypothesis that heavy cigarette smoking was associated with worse allo-HSCT outcomes, with a focus on IFI.
We performed a retrospective analysis of 291 adult patients who received myeloablative allo-HCT for any indication at the Cleveland Clinic between January 2004 and December 2010. This study was reviewed and approved by the Cleveland Clinic Institutional Review Board and all patients had previously signed IRB-approved consent forms for research purposes. End points included relapse, relapse mortality, non-relapse mortality, overall survival (OS) and IFI.
Patient demographics and most study variables were extracted using standardized formats. Exploratory analysis using Cox proportional hazards analysis for OS and Fine and Gray regression for other outcomes suggested that the cutoff of 20 pack-years may be associated with impaired survival. Therefore, patients were stratified into two groups: heavy tobacco use with 20 or more pack-years of smoking and another group with o 20 pack-years (including non-smokers). Twenty-four patients with missing packyear data were excluded from the analysis. Data regarding potential IFI was initially extracted from the transplant database. The electronic medical records were then evaluated by one of the authors (AM) and 47 events were considered to represent IFI. Those were further classified into possible, probable and proven IFI based on standard diagnostic criteria from consensus guidelines. 8 Mycological evidence was required for proven and probable IFI, whereas convincing clinical criteria alone were sufficient for possible cases. Stratified cases were reviewed with one of the study authors (SM) who is a transplant infectious disease specialist and consensus categorization with the primary author was established. Note that all patients undergoing transplantation are maintained on amoxicillin, acyclovir and itraconazole. If daily prednisone dose exceeded 30 mg/day, itraconazole is replaced by either voriconazole or posaconazole.
Baseline characteristics were compared between the two smoking groups using the χ 2 -test (categorical variables) or Wilcoxon rank-sum test (continuous variables). Post-transplant outcomes were assessed from the date of transplant. OS was estimated using the Kaplan-Meier method and compared between groups using the log-rank test; all other outcomes were estimated using cumulative incidence method and compared using the Gray test. Risk factors for mortality (OS) were assessed using Cox proportional hazards analysis; risk factors for all other outcomes were assessed using Fine and Gray competing risk regression. Variables considered included age, gender, race, Overall 9.0% of transplant recipients were current smokers at the time of transplant with 20.6% being former smokers. Outcomes were initially compared between non-smokers, o 20 pack-year smokers and ⩾ 20 pack-year smokers. No significant difference was noted in OS between non-smokers and those with light smoking history (median OS: 2.5 vs 1.3 years; P = 0.62). These groups were thus combined for subsequent analysis. Baseline patient and transplant characteristics of patients with ⩾ 20 packyear smoking history (n = 40) and those with o 20 pack-years (n = 227) including non-smokers (n = 188) showed that the heavysmoking group was older (median age 51 vs 46, P = 0.002), more often male (67.5% vs 49.3%, P = 0.034) and had worse baseline respiratory function. No other patient or transplant characteristic differed between groups, including length of hospitalization and days until hematopoietic reconstitution. Patients were followed for a median of 51.2 months (range: 1.2-111.0).
In univariate analysis, OS was significantly worse in the heavysmoking group compared to the non-smoker/light-smoker group (hazards ratio (HR) 1.54, 95% confidence interval (CI) 1.03-2.29, P = 0.034) ( Table 1 and Figure 1a) , with estimated 5-year survival 19.4% and 42.4%, respectively. This result remained significant in multivariable analysis (HR 1.63, 95% CI 1.08-2.46, P = 0.021) ( Table 1) . Non-relapse mortality (NRM) was also worse in the heavy-smoking group on univariate analysis (HR 1.65, 95% CI 1.03-2.66, P = 0.039), but was attenuated on multivariable analysis (HR 1.44, 95% CI 0.88-2.36, P = 0.15). No significant difference in relapse or relapse mortality was seen between the two groups. Moreover, the smoking effect on NRM was noted to be dosedependent (HR 1.36, 95% CI 1.07-1.72, P = 0.012).
IFI developed in 27.5% of patients in the heavy-smoking group and 15.9% of patients in the o 20 pack-year group. To further clarify the relationship between smoking and IFI, we performed two distinct analyses. In the first one, we only considered the proven and probable infections. An increase in the IFI was seen in the heavy-smoking group with a trend for significance (HR 2.54, 95% CI 0.98-6.58, P = 0.06) (Figure 1b) . A similar trend was also noted when the analysis was carried with all IFI including the possible cases. Notably, there was no difference in the GvHD prophylaxis regimen or in the severity of the acute or chronic GvHD that developed in the two smoking groups (P = 0.19 for any acute GvHD, P = 0.96 for any chronic GvHD). Proven and probable IFI were associated with significantly higher mortality on univariate analysis (HR 5.00, 95% CI 2.97-8.44, P o0.001) ( Table 1 ). This observation remained significant in multivariable analysis (HR 4.97, 95% CI 2.93-8.44, P o 0.001) ( Table 1) . When the analysis was carried with all IFI including the possible cases, a similar association was also evident (Table 1) .
Our cohort demonstrates a statistically significant lower OS among heavy smokers receiving allo-HCT defined as smoking 20 pack-years or more, relative to the non-smoker/light-smoker group. Relapse and relapse mortality were not different between the two groups. Differences in OS appear to have been mediated by an increased NRM in heavy smokers. Although our data did not demonstrate a dose-dependent survival benefit, heavy smokers had inferior OS than the non-smokers/light-smoker group. Similar results were also seen in a large retrospective study of CML patients by Marks et al., 4 in which an 18% higher mortality rate was observed among smokers. Ehlers et al. 9 observed similar results among acute leukemia patients in which a 24% lower 3-year survival rate was observed among current smokers.
Conversely, Hanajiri et al. 5 did not find any association between smoking and OS or NRM among transplant recipients. In this study however, non-myeloablative transplants were also included in the analysis, which might have accounted for the observed difference.
Infectious complications after transplant have been linked to smoking in some studies. 4, 9, 10 In a recent large prospective multicenter study evaluating pre-chemotherapy risk factors for IFI in a cohort of 1192 patients with newly diagnosed AML, Caira et al.
11 found smoking to be associated with invasive mold infections only on univariate analysis. No association was found between smoking and yeast infections. In our cohort, we observed an increase in proven and probable IFI among heavy smokers that approached statistical significance. Our study thus confirms higher infectious complications in high-dose smokers with a highly suggestive trend toward an increase in IFI. Stratifying patients at risk for IFI is justified, given the poor outcomes associated with it in allo-HCT. 10, 12 In a recent large prospective study by the Gruppo Italiano Trapianto Midollo Osseo of 1858 consecutive allo-HCT recipients, IFI (proven or probable) was an independent factor in long-term survival. 13 Our study supports the findings of this study as IFI, whether defined as proven/ probable or any (including possible) was significantly associated with lower survival on univariate and multivariable analysis.
In conclusion, to our knowledge, this is the first study attempting to evaluate the potential relationship between smoking and IFI among allo-HCT recipients. A lower OS was observed in heavy smokers mediated by an increase in NRM with a trend toward more fungal infectious complications. Realizing that smoking might decrease survival through more than one mechanism, the association with increased IFI highlights several questions. Whether an increase in the IFI is a mechanism of increased NRM in heavy smokers warrants further exploration. The retrospective nature of our study is a limitation that warrants prospective evaluation to gain new insights into the optimal management of smoking patients undergoing allo-HCT.
